精准生物科技公司已正式启动其首个临床试验中心,并开始为功能型杜氏肌营养不良症(Function-Dmd)的1/2期研究招募患者。这一关键进展标志着公司针对该罕见病的新型基因疗法正式进入临床验证阶段。
此次启动的临床试验旨在评估创新疗法的安全性与有效性,为后续研究奠定基础。患者招募工作的启动意味着符合条件的个体将有机会参与这项前沿医学研究。
精准生物科技公司已正式启动其首个临床试验中心,并开始为功能型杜氏肌营养不良症(Function-Dmd)的1/2期研究招募患者。这一关键进展标志着公司针对该罕见病的新型基因疗法正式进入临床验证阶段。
此次启动的临床试验旨在评估创新疗法的安全性与有效性,为后续研究奠定基础。患者招募工作的启动意味着符合条件的个体将有机会参与这项前沿医学研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.